Trials / Completed
CompletedNCT01698060
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of ND1.1 by Delivery Directly to the Ileum Using the InteliSite® Companion Capsule in Healthy Adult Males
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Vaxart · Industry
- Sex
- Male
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to determine the safety and tolerability of ND1.1, an adjuvanted adenoviral-based avian influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses of ND1.1 oral vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ND1.1 |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2012-10-02
- Last updated
- 2014-12-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01698060. Inclusion in this directory is not an endorsement.